.
Mutated neo-antigens in hepatocellular carcinoma (HEPAMUT)
Project/agreement No.
ES RTD/2017/20
Project funding
210 000.00 EUR
Project manager
Project realization
20.02.2017. - 19.02.2020.
Aim
The primary objective is to evaluate genetically modified epitope immunogenicity in HLA transgenic mice in vivo and their therapeutic effect in the HCC-PDX animal model
Specific goals: Identification of specific, genetically modified antigens of hepatocellular carcinoma using new generation sequencing and evaluation of specific T cell response in vitro, before and after therapy
Evaluation of genetically altered epitope immunogenicity in HLA transgenic mice in vivo and their therapeutic effect in the HCC-PDX animal model
Identification of protein-specific, genetically modified cell-surface specific full-length hepatocellular carcinoma cells and immune evaluation in vivo
Specific goals: Identification of specific, genetically modified antigens of hepatocellular carcinoma using new generation sequencing and evaluation of specific T cell response in vitro, before and after therapy
Evaluation of genetically altered epitope immunogenicity in HLA transgenic mice in vivo and their therapeutic effect in the HCC-PDX animal model
Identification of protein-specific, genetically modified cell-surface specific full-length hepatocellular carcinoma cells and immune evaluation in vivo
Description
Project activities
Identification of mutant neoantigens in liver carcinoma of different aetiology and assessment of in vitro T cell specific response after treatment with cell cycle inhibitors
Identification of selected mutant epitopes in vivo using HLA transgenic mice and their therapeutic effect in a HCC-PDX animal model
Project partners
- Istituto Nazionale Tumori “Pascale” (INTNA), Italy - Lead partner
- University of Nantes, France
- Clinica Universidad de Navarra, Spain
- University of Leuven, Belgium
- Ospedale San Raffaele, Italy
- Competence Centre of Cancer Research, Estonia
www.hepamut.eu
